$FULC News

Fulcrum: 'Hold' On Pociredir Discontinuation And Strategic Alternatives Shift

JP Morgan Downgrades Fulcrum Therapeutics to Underweight

Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3

Piper Sandler Downgrades Fulcrum Therapeutics to Underweight, Lowers Price Target to $3

Truist Securities Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $4

Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4

HC Wainwright & Co. Downgrades Fulcrum Therapeutics to Neutral, Lowers Price Target to $3

FULC Stock Crashes After Hours: What Investors Need To Know

Fulcrum Therapeutics Launches Strategic Alternatives Review To Maximize Shareholder Value

Fulcrum Discontinues Pociredir Program For Treatment Of Sickle Cell Disease After FDA Flags Concerns About Malignancy Risk From PRC2 Inhibitors

Fulcrum Therapeutics (NASDAQ:FULC) Beats Q1 Estimates as Pociredir Data Fuels Optimism

Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call Transcript

Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript

Fulcrum Therapeutics Q1 EPS $(0.25) Beats $(0.30) Estimate, Ended The First Quarter Of 2026 With $333.3M In Cash, Cash Equivalents, And Marketable Securities; Cash Runway Into 2029

Fulcrum Therapeutics Q1 EPS $(0.25) Beats $(0.30) Estimate, Ended The First Quarter Of 2026 With $333.3M In Cash, Cash Equivalents, And Marketable Securities; Cash Runway Into 2029

MedicAlert Foundation, SCDAA And Fulcrum Therapeutics Partner To Help Streamline And Expedite ED Care For People Living With Sickle Cell Disease Through Rapid Access To Patient-Specific Care Plans

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion

Fulcrum Therapeutics move lower ‘overdone,’ says Stifel